Loading...
  • drug
  • However, an even smaller proportion of newly diagnosed people - just three cases in ten years, or one in 606 of those diagnosed - had primary drug resistance, i.e. actually became infected with tenofovir/emtricitabine-resistant HIV, and this is more likely to reflect the maximum frequency of people who could acquire drug-resistant HIV from someone else despite being on PrEP. (nhivna.org)
  • Susan Buskin and colleagues from Public Health Seattle and the University of Washington searched through drug resistance test records from 2003 to the end of 2017 to establish the frequency of high- and low-level resistance to tenofovir and emtricitabine. (nhivna.org)
  • proportion
  • If the proportion of people with high-level resistance who had not had a resistance test was the same, this would imply another nine people with substantial viraemia. (nhivna.org)
  • PrEP
  • This is likely to be a maximum, as before about 2008 people were only likely to have had a resistance test if resistance was already suspected, but it means there were possibly about 20 people in King County with both substantial viraemia and resistance to the PrEP drugs, or one in 331 of those diagnosed, during the period studied. (nhivna.org)
  • high
  • Out of these 246 (6%) had high-level tenofovir/emtricitabine resistance, while at the last round of viral load tests 310 had substantial viraemia, or roughly 5% of people diagnosed. (nhivna.org)
  • However, only 12 people (0.3% of those with resistance tests, or one in 323 people) had both high-level resistance and substantial viraemia. (nhivna.org)
  • People with high-level tenofovir and emtricitabine resistance were older, predominantly over 50, and had been diagnosed substantially longer than people without resistance: their average year of diagnosis was 1994 compared with 2005 for people without tenofovir/emtricitabine resistance. (nhivna.org)
  • reduce
  • Recent studies have demonstrated that genetically modified hematopoietic stem cells (HSCs) can reduce HIV viremia. (nih.gov)
  • primary
  • A survey was also carried out, therefore, to calculate the number of people who were diagnosed with primary tenofovir/emtricitabine resistance - i.e. they had acquired it through transmission. (nhivna.org)